Haleon exploring sale of ChapStick Brand - report
Eva-Katalin/E+ via Getty Images
- Haleon Plc (NYSE:HLN), the consumer health unit spun off from GSK Plc last year, is evaluating a sale of its ChapStick lip balm brand.
- The company is working with advisers and the business could see $600 million in a potential sale, according to a Bloomberg report from Friday, which cited people familiar. Deliberations on a possible sale are said to be at an early stage.
- The news comes after Bloomberg late last month reported that Haleon (HLN) was in the early stages of evaluating large potential deals to increase the size of its brand portfolio. Haleon was said to be studying possible deals in the medium-to-long-term, including potentially combining with Sanofi's (SNY) $30 billion consumer-health business.
- Haleon (HLN) is set to report Q4 results on Thursday.
- Also see SA contributor Yannick Frey's piece from last month entitled "Haleon: A Great Consumer Staples Add."